within Pharmacolibrary.Drugs.ATC.B;

model B03BA53
  extends Pharmacokinetic.Models.PK_2C(
    weight         = 70,
    F              = 1,
    Cl             = 7.5e-06,
    adminDuration  = 600,
    adminMass      = 500 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.012,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,            
    Vdp             = 0.003,
    k12             = 0.25,
    k21             = 0.25
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>B03BA53</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Hydroxocobalamin is a form of vitamin B12, used primarily for the treatment of vitamin B12 deficiency and as an antidote to cyanide poisoning. In combination products (ATC code B03BA53), it may be co-formulated with other vitamins or minerals for parenteral supplementation, but such combinations are not widely approved or available in all countries.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters for hydroxocobalamin, combinations (ATC B03BA53) have not been specifically published. The following estimates are based on the pharmacokinetics of hydroxocobalamin monotherapy in healthy adults after intravenous administration.</p><h4>References</h4><ol><li><p>Thompson, JP, &amp; Marrs, TC (2012). Hydroxocobalamin in cyanide poisoning. <i>Clinical toxicology (Philadelphia, Pa.)</i> 50(10) 875–885. DOI:<a href=\"https://doi.org/10.3109/15563650.2012.742197\">10.3109/15563650.2012.742197</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/23163594/\">https://pubmed.ncbi.nlm.nih.gov/23163594</a></p></li><li><p>Shepherd, G, &amp; Velez, LI (2008). Role of hydroxocobalamin in acute cyanide poisoning. <i>The Annals of pharmacotherapy</i> 42(5) 661–669. DOI:<a href=\"https://doi.org/10.1345/aph.1K559\">10.1345/aph.1K559</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/18397973/\">https://pubmed.ncbi.nlm.nih.gov/18397973</a></p></li><li><p>Forsyth, JC, et al., &amp; Hall, AH (1993). Hydroxocobalamin as a cyanide antidote: safety, efficacy and pharmacokinetics in heavily smoking normal volunteers. <i>Journal of toxicology. Clinical toxicology</i> 31(2) 277–294. DOI:<a href=\"https://doi.org/10.3109/15563659309000395\">10.3109/15563659309000395</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/8492341/\">https://pubmed.ncbi.nlm.nih.gov/8492341</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end B03BA53;
